Phase 3 trial | sciencenewsnet.in

Breaking News

Future Parents More Likely to Get RSV Vaccine When Pregnant if Aware That RSV Can Be a Serious Illness in Infants

Transforming Agriculture and Medicine: The Impact of Gene-Based Breeding (GBB)

Advancing CBSD Resistance in Cassava: A Comprehensive Review of Breeding Strategies and the Role of New Plant Technologies

ADDMAN Secures Qualification Project for CuNi Submarine Fittings with the US Navy

It’s easier now to treat opioid addiction with medication — but use has changed little

Researchers Publish Final Results of Key Clinical Trial for Gene Therapy for Sickle Cell Disease

A new report from the American Lung Association shows nearly 40% of people across the U.S. are living in areas that are heavily polluted.

Five facilities at Argonne where climate solutions are front and center

For Immigrants to Canada, Risk of MS Increases with Proportion of Life Spent There

Use of Acid Reflux Drugs Linked to Higher Risk of Migraine

25 Apr, 2024

Phase 3 study finds fezolinetant reduces the frequency and severity of menopausal hot flashes

June 11, 2022 sarah JonasResearch Results

Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with menopause, according to a Phase 3 industry-sponsored study being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.

Are Too Many Phase III Cancer Clinical Trials Set Up to Fail?

September 23, 2021 sarah JonasResearch Results

New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.

Baylor Scott & White Health Enrolls First Patients in the World in Trial for Inhaled Remdesivir

October 2, 2020 sarah JonasFeature

Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.